Results 121 to 130 of about 7,531 (200)

MF59™ as a vaccine adjuvant: a review of safety and immunogenicity

Expert Review of Vaccines, 2010
Approximately 70 years passed between the licensing of alum salts as vaccine adjuvants and that of MF59™ MF59, an oil-in-water emulsion, is currently licensed for use in the elderly as an adjuvant in seasonal influenza vaccines. Its mechanism of action is not fully understood, but enhancement of the interaction between the antigen and the dendritic ...
openaire   +1 more source

Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1-2 randomized double-blind placebo-controlled trial.

PLOS Global Public Health
Induction of broad, durable immune responses is a challenge in HIV vaccine development. HVTN 100 Part A administered subtype C-containing ALVAC-HIV at months 0 and 1, and ALVAC-HIV with bivalent subtype C gp120/MF59 at months 3, 6 and 12.
Vimla Naicker, Fatima Laher, Linda-Gail Bekker, Kelly E Seaton, Mary Allen, Stephen De Rosa, Nicole L Yates, Nonhlanhla N Mkhize, Kevin Saunders, Jack Heptinstall, Mookho Malahleha, Kathryn Mngadi, Brodie Daniels, Craig Innes, Chenchen Yu, Tandile Modise, Valerie Bekker, Nicole Grunenberg, Briana Furch, Maurine D Miner, Sanjay Phogat, Carlos A Diazgranados, Sanjay Gurunathan, Marguerite Koutsoukos, Olivier Van Der Meeren, Alison C Roxby, Guido Ferrari, Lynn Morris, David Montefiori, M Juliana McElrath, Georgia D Tomaras, Zoe Moodie   +31 more
doaj   +1 more source

Influenza vaccination: Options and issues [PDF]

, 2005
Currently available vaccines have similar efficacy if they are matched to the most prevalent circulating strains. They also have comparable adverse effect profiles. The choice of a specific preparation of vaccine therefore requires consideration of cost,
Wong, SSY, Yuen, KY
core  

Humoral Response to the Influenza A H1N1/09 Monovalent AS03-Adjuvanted Vaccine in Immunocompromised Patients [PDF]

, 2017
In this observational study, safety and immunogenicity after one dose of the AS03-adjuvanted influenza H1N1/09 vaccine was overall appropriate in HIV-infected patients and solid-organ transplant recipients.
Alves, Deolinda, Bart, Pierre-Alexandre, Calandra, Thierry, Cavassini, Matthias, Ellefsen, Kim, Giulieri, Stefano, Hoschler, Katja, Manuel, Oriol, Pascual, Manuel, Venetz, Jean-Pierre   +9 more
core  

Virology [PDF]

Avian influenza viruses, notably H5 subtype viruses, pose a continuous threat to public health due to their pandemic potential. In recent years, influenza virus H5 subtype split vaccines with novel oil-in-water emulsion based adjuvants (e.g.

core  

Evaluation of Polymyxin B as a Novel Vaccine Adjuvant and Its Immunological Comparison with FDA-Approved Adjuvants. [PDF]

Vaccines (Basel)
Gulani M, Harsoda Y, Arte T, D'Souza MJ, Bagwe P, Adediran E, D'Souza N, Pasupuleti D.   +7 more
europepmc   +1 more source

Cross-herpesvirus immunity of the cytomegalovirus gB/MF59 vaccine response. [PDF]

NPJ Vaccines
Lankina A, Hargreaves A, Lui WT, Kropff B, Wei A, Breuer J, White RE, Thomas M, Griffiths PD, Reeves MB.   +9 more
europepmc   +1 more source

Sıtma aşısında alternatif kombinasyon: Plasmodium falciparum Circumsporozoite protein ve MF59

, 2020
Malaria is the leading cause of death, amongst the parasitic diseases. Malaria is caused by parasitic protozoans belonging to the genus Plasmodium. The disease is transmitted to the human by the biting of female Anopheles mosquitos. Malaria is a curable disease if diagnosed and treated promptly and correctly.
openaire   +1 more source

The potential for a protective vaccine for rhinovirus infections. [PDF]

, 2016
Glanville, NS, Johnston, SL, Kubajewska, I, Mclean, GR, Williams, GR   +4 more
core   +2 more sources

Preclinical development of a cross-protective β-SARS-CoV-2 virus-like particle vaccine adjuvanted with MF59. [PDF]

NPJ Vaccines
Earnest L, Ruiz DF, Edeling MA, Montoya JC, Yap AHY, Wong CY, Holz LE, Gras S, Collett S, Cooney JP, Davidson KC, Grimley SL, Purcell DFJ, Roberts J, Mumford J, Tan CW, Wang LF, Godfrey DI, Frieman M, Hans D, Vincan E, Anderson DE, Subbarao K, Pellegrini M, Mackenzie JM, Rockman S, Heath WR, Torresi J.   +27 more
europepmc   +1 more source